Skip to content
Oligon Logo

Pipeline of
Therapeutic Programs

Pipeline of Innovative RNA Therapeutics

Multitargeting SeekR Programs
Pipeline of Therapeutic Programs

OLI-0101 Anti-Cancer SeekR Program

Multitargeting SeekR™ to trigger synthetic lethality in colon tumors
Lead Candidate: aptEpCAM + siTargetSL + aptHER3
Binders direct siRNA into colon cancer cells that co-express EpCAM and Her3 Receptors
Silencers target genes that are conditionally essential for cancer cells (synthetic lethal)
Stage
Clinical Focus
Strategy & Impact

OLI-0102 Anti-Cancer SeekR Program

Multitargeting SeekR™ to trigger synthetic lethality in lung/breast tumors
Lead Candidate: aptTROP2 + siTargetSL + aptHER3
Binders direct siRNA into Lung/Breast cancer cells that co-express TROP2 and Her3 Receptors
Silencers target genes that are conditionally essential for cancer cells (synthetic lethal)
Stage
Clinical Focus
Strategy & Impact

OLI-0103 Anti-Cancer SeekR Program

Multitargeting SeekR™ to trigger synthetic lethality in prostate tumors
Lead Candidate: aptTROP2 + siTargetSL + siTargetO aptPSMA
Binders direct siRNA into prostate cancer cells that co-express TROP2 and PSMA Receptors
Silencers target genes that are conditionally essential for cancer cells (synthetic lethal)
Stage
Clinical Focus
Strategy & Impact

OLI-0201 T-Cell Directed IO Program

Multitargeting SeekR™ T-cell based solid tumor immunotherapy
Lead Candidate: aptPD1 + siTargetX + siTargetY + aptCTLA4
Binders block both PD1 and CTLA4 checkpoints and direct siRNA into T-cells
Silencers block two forms of IO resistance (T-cell exhaustion + TIL toxicity)
Stage
Clinical Focus
Strategy & Impact

OLI-0301 Cancer Directed IO Program

Multitargeting SeekR™ cancer cell directed solid tumor IO therapy
Lead Candidate: aptEpCAM + siTargetA + siTargetB + aptEpCAM
Aptamer binders direct siRNA into cancer cells
siRNA silencers block two key targets in cancer cells in order to reverse immune resistance
Stage
Clinical Focus
Strategy & Impact

OLI-0401 Endothelial Cell Targeting IO Program

Multitargeting SeekR™ therapeutics to reverse atherosclerosis
Lead Candidate: aptVCAM + anti-miC + anti-mirD + aptICAM
Aptamer binders direct siRNA into endothelial cells
Anti-microRNA oligos inhibit key miRNA involved in the pathogenesis of atherosclerosis
Stage
Clinical Focus
Strategy & Impact